PlumX Metrics
Embed PlumX Metrics

Clofazimine as a treatment for multidrug-resistant tuberculosis: A review

Scientia Pharmaceutica, ISSN: 2218-0532, Vol: 89, Issue: 2
2021
  • 15
    Citations
  • 0
    Usage
  • 95
    Captures
  • 1
    Mentions
  • 23
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    15
    • Citation Indexes
      15
  • Captures
    95
  • Mentions
    1
    • Blog Mentions
      1
      • Blog
        1
  • Social Media
    23
    • Shares, Likes & Comments
      23
      • Facebook
        23

Review Description

Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease caused by Mycobacterium tuberculosis which is resistant to at least isoniazid and rifampicin. This disease is a worldwide threat and complicates the control of tuberculosis (TB). Long treatment duration, a combination of several drugs, and the adverse effects of these drugs are the factors that play a role in the poor outcomes of MDR-TB patients. There have been many studies with repurposed drugs to improve MDR-TB outcomes, including clofazimine. Clofazimine recently moved from group 5 to group B of drugs that are used to treat MDR-TB. This drug belongs to the riminophenazine class, which has lipophilic characteristics and was previously discovered to treat TB and approved for leprosy. This review discusses the role of clofazimine as a treatment component in patients with MDR-TB, and the drug’s properties. In addition, we discuss the efficacy, safety, and tolerability of clofazimine for treating MDR-TB. This study concludes that the clofazimine-containing regimen has better efficacy compared with the standard one and is also well-tolerated. Clofazimine has the potential to shorten the duration of MDR-TB treatment.

Bibliographic Details

Rhea Veda Nugraha; Vycke Yunivita; Rovina Ruslami; Prayudi Santoso; Rob E. Aarnoutse

MDPI AG

Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know